Author Archives : Editorial Team

Home  >>  Author : Editorial Team

Press Release: “Proposal Writing Training for H2020 applications“

On March 8, 2018, Posted by , In Press Releases, By , With Comments Off on Press Release: “Proposal Writing Training for H2020 applications“

Heidelberg, 08.03.2018 BioRN together with the German national contact point (Nationale Kontakstellen – NKS), organised on Wednesday, April the 7th a training for H2020 applications writing. Potential applicants with a concrete project in their pipeline were admitted to the training and could discuss technical improvements and pitfalls with the experts….

New EMBL spinoff company Velabs Therapeutics to accelerate antibody discovery

On March 8, 2018, Posted by , In News, By , , With Comments Off on New EMBL spinoff company Velabs Therapeutics to accelerate antibody discovery

An established proprietary microfluidics technology from the European Molecular Biology Laboratory (EMBL) allows for fast screening of antibodies from natural sources and even difficult targets. With the startup company Velabs Therapeutics, launched by EMBL and its technology transfer arm EMBLEM Technology Transfer GmbH (EMBLEM) together with private investors, the advantages…

EMBL recognises the outstanding work of alumni with the John Kendrew and Lennart Philipson Awards

On March 7, 2018, Posted by , In News, By , , With Comments Off on EMBL recognises the outstanding work of alumni with the John Kendrew and Lennart Philipson Awards

From Big Data to viral enzymes, EMBL alumni are tackling questions across the full range of science disciplines. This year’s alumni awards celebrate this diversity by showcasing the work of Nils Gehlenborg, winner of the 2018 John Kendrew Young Scientist Award, and Raffaele De Francesco, winner of the 2018 Lennart Philipson Award….

GSK: New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

On March 6, 2018, Posted by , In News, By , , With Comments Off on GSK: New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

GSK today announced new data published in The Lancet Child & Adolescent Health from a Phase III clinical trial with Fluarix Tetra (inactivated quadrivalent influenza vaccine [IIV4]) which prevented influenza A and B in children six to 35 months of age. Vaccine efficacy was highest against moderate-to-severe influenza, where the…